Clinical trials: Zoledronic acid, completed
Osteoporosis
Study to Investigate the Efficacy and Safety After Administration of Daewoong Zoledronic Acid for the Purpose of Treatment or Prevention of Osteoporosis
This study is a non-interventional observational study. On the baseline (Visit 1), we collect demographic data from all participating subjects according to their daily medical conditions, prescribe drugs and collect validity and…
- Trial name
- NCT05614778
- Testing
- Zoledronic Acid injection, 5mg/100mL
- Where
- South Korea
- Volunteers
- 2,881 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Spinal Cord Injury, Acute Spinal Cord Injury
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
The overall objective of this study is to define an effective therapeutic approach, using currently available medication, to prevent or mitigate the loss of bone mass and bone strength that occurs after acute spinal cord injury.
- Conditions
- Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
- Trial name
- NCT02325414
- Testing
- Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Breast Cancer
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171314
- Testing
- Zoledronic acid, Letrozole
- Where
- 49 sites in Argentina, Belgium and 7 more
- Volunteers
- 527 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study
Investigators will test the hypothesis that an increase in bone turnover markers (e.g. carboxy-terminal collagen crosslinks (CTX) and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who…
- Trial name
- NCT04177940
- Testing
- DMAB Discontinuation and Switching
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Alabama at Birmingham
Disuse Osteoporosis
Zoledronic Acid Administration in Acute Spinal Cord Injury
In subjects with acute SCI: To compare the effects of parenteral zoledronic acid therapy on preservation of regional and total skeletal mass (DXA).
- Trial name
- NCT02042872
- Testing
- Zoledronic acid
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Non-Small Cell Lung Cancer
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
This randomized phase 2 trial is studying the effect of adding denosumab to standard chemotherapy in the treatment of advanced lung cancer.
- Trial name
- NCT01951586
- Testing
- Denosumab, Zoledronic acid, Standard Chemotherapy
- Where
- 74 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Amgen
Metastatic Prostate Cancer
ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer
This phase I trial is studying the side effects and best dose of docetaxel when given with zoledronic acid in patients with bone metastasis from prostate cancer that has not responded to hormone therapy.
- Trial name
- ZANTE (NCT00415779)
- Testing
- docetaxel, zoledronic acid
- Where
- 2 sites in Italy
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute, Naples
Post Menopausal Osteoporosis
Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
This study will compare the effectiveness of denosumab treatment every 6 months with once yearly zoledronic acid treatment on bone mineral density (BMD) at various skeletal sites.
- Trial name
- NCT01732770
- Testing
- Denosumab, Zoledronic Acid
- Where
- 45 sites in United States, Australia and 5 more
- Volunteers
- 643 people
- Sponsor
- Amgen
Leiomyosarcoma
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
Dinutuximab beta was designed to bind to neuroblastoma cells and other cancer cells that express the GD2 antigen, such as STS/LMS cells, and it is believed that this binding "labels" the cells an makes them a better target.
- Trial name
- DiTuSarc (NCT05080790)
- Testing
- Dinutuximab Beta, Zoledronic acid, Interleukin-2
- Where
- 2 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Prostate Cancer With Bone Metastasis
Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis
Study to determine effectiveness and safety of zoledronic acid and whether it has a pharmaco-economic impact in prostate cancer with bone metastasis.
- Trial name
- NCT00241111
- Testing
- zoledronic acid
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Low Back Pain
The Efficacy of Zoledronic Acid in Modic Changes-related Low Back Pain (LBP)
Modic changes are associated with low back pain (LBP) both in clinical and general population-based samples. Type I changes are regarded as more likely to be painful than type II changes.
- Trial name
- NCT01330238
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- University of Oulu
Breast Neoplasms, Osteoporosis
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip…
- Trial name
- NCT00050011
- Testing
- Zoledronic Acid, Letrozole
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
The purpose of this study is to assess the efficacy and tolerability of zoledronic acid in preventing skeletal-related events in patients with prostate cancer
- Trial name
- NCT00172016
- Testing
- Zoledronic acid
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Osteoporosis
Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
RATIONALE: Zoledronate may reduce bone loss in patients receiving letrozole for breast cancer. PURPOSE: This clinical trial is studying how well zoledronate works in treating osteopenia or osteoporosis in postmenopausal women…
- Trial name
- NCT00436917
- Testing
- zoledronic acid, Letrozole as adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Osteoporosis
The Optimal Sequential Therapy After Long Term Denosumab Treatment
This study intends to investigate whether Alendronate and Zoledronate can prevent bone mineral density loss after long-term treatment with Denosumab.
- Trial name
- NCT05091099
- Testing
- zoledronate, Alendronate and Zoledronate
- Where
- Taiwan
- Volunteers
- 44 people
- Sponsor
- National Taiwan University Hospital
Secondary Osteoporosis
Efficacy of Zoledronic Acid + Colaren vs Zoledronic Acid + Conventional Treatment for Osteoporosis in HIV+ and HIV- Men
Clinical trial to assess the effectiveness of the supplement Colaren® associated with zoledronic acid 4mg/annually in the treatment of osteoporosis secondary, compared to standard treatment plus zoledronic acid 4mg/annually.
- Trial name
- OSZCO (NCT03930992)
- Testing
- Colaren in HIV positive, standard treatment in HIV positive, Colaren in HIV negative
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- University of Guadalajara
Breast Cancer, Prostate Cancer
Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
This is an open-label exploratory study of CTAP101 Capsules in patients with bone metastases arising from either breast or prostate cancer, who are taking anti-resorptive therapy.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Neoplasms, Hypocalcemia
- Trial name
- NCT02274623
- Testing
- CTAP101 Capsules
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- OPKO Health, Inc.
Multiple Disability, Osteoporosis
Efficacy of Zoledronic Acid in Osteoporosis of Children With Multiple Disabilities
The main purpose of this study is the evaluation of the efficacy of zoledronic acid on bone density in children with osteoporosis caused by multiple disabilities. Secondary purposes are: 1.
- Trial name
- ZOMETA (NCT03301285)
- Testing
- Zoledronic Acid
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Central Hospital, Nancy, France
Osteogenesis Imperfecta
An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta
The investigators have currently finished conducting an international multi-center trial that compares the efficacy and safety of pamidronate and zoledronate in the treatment of moderate to severe forms of Osteogenesis Imperfecta…
- Trial name
- INFOI (NCT00982124)
- Testing
- Zoledronic Acid
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Shriners Hospitals for Children
Bariatric Surgery Candidate, Bone Loss
Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
Bariatric surgery leads to bone loss and increases fracture risk. This study evaluates whether denosumab can prevent the high-turnover bone loss that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG)…
- Trial name
- NCT04087096
- Testing
- Denosumab, Zoledronic Acid
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital